Article Text

other Versions

PDF
Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease

Statistics from Altmetric.com

This is a PDF-only article. The first page of the PDF of this article appears below.

PDF extract preview
  • Conflict of interest: DWH is supported by a grant from The Netherlands Organization for Health Research and Development, and is a consultant for Protein Design Labs. GvA is a consultant for Protein Design Labs. SB and TP are employees of Protein Design Labs, Inc. None declared by the other authors.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles